Breast milk drug check: HIV med levels measured in nursing moms
NCT ID NCT07086079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study enrolled 12 healthy lactating women to measure how much of the HIV drug MK-8591A (doravirine and islatravir) gets into breast milk. Participants took one oral tablet and provided breast milk and blood samples over 24 hours. The goal was to estimate the dose a nursing infant might receive, helping guide future safety recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-8591A (doravirine and islatravir combination tablet)
- What this could lead to
- If successful, this study could help doctors understand whether MK-8591A is safe for breastfeeding mothers and their infants.
- What could go wrong
- This is a very small, early-stage study in healthy women, not people with HIV. Results may not apply to real-world patients, and the drug could still be unsafe for infants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
QPS Missouri ( Site 0001)
Springfield, Missouri, 65802, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test